Translational development of splice-modifying antisense oligomers.

Area of Science:

• Molecular Biology
• Genetics
• Pharmacology

Background:

• Antisense nucleic acid analogues modulate gene expression by interacting with pre-mRNA.
• This interaction influences alternative splicing, leading to exon exclusion or inclusion.
• The antisense concept is being developed for rare, life-limiting diseases.

Purpose of the Study:

• To review the clinical translation of novel antisense therapeutics for Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA).
• To highlight challenges in clinical trials for rare diseases, including small patient numbers and variable disease progression.
• To discuss strategies for effective clinical evaluation and outcome measure identification.

Main Methods:

• Review of current literature on antisense-mediated splice intervention.
• Analysis of clinical trial designs and challenges in rare neuromuscular disorders.
• Discussion of expert opinions on therapeutic development and regulatory cooperation.

Main Results:

• Antisense-mediated splice intervention shows promise for treating DMD and SMA.
• Clinical translation faces hurdles such as limited patient cohorts and defining endpoints.
• Multidisciplinary research, industry partnerships, and patient engagement accelerate progress.

Conclusions:

• Successful translation of novel therapeutics for DMD and SMA relies on collaboration and patient support.
• Adaptive trial designs are suitable for evaluating therapeutics in rare diseases.
• Cooperation among sponsors, supporters, and regulators is crucial for delivering new drugs.